Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.

Xinyuan GuChunyan SunJuan XuZhimei LinLi Zhang Yuhuan Zheng

Published in: Hematology (Amsterdam, Netherlands) (2023)

In conclusion, using selinexor as the fifth-line or prior therapy had a beneficial impact on RRMM. The regimen of Xd plus PIs or IMiDs was recommended.

Keyphrases

multiple myeloma
emergency department
stem cells
cell therapy
smoking cessation